225 related articles for article (PubMed ID: 33634707)
1. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with
Pienta KJ; Gorin MA; Rowe SP; Carroll PR; Pouliot F; Probst S; Saperstein L; Preston MA; Alva AS; Patnaik A; Durack JC; Stambler N; Lin T; Jensen J; Wong V; Siegel BA; Morris MJ
J Urol; 2021 Jul; 206(1):52-61. PubMed ID: 33634707
[TBL] [Abstract][Full Text] [Related]
2. Predicting
Lee KH; Mena E; Shih J; Lindenberg L; Wood BJ; Pinto PA; Patel KR; Citrin DE; Choyke PL; Turkbey B
Acad Radiol; 2024 Apr; 31(4):1419-1428. PubMed ID: 37775447
[TBL] [Abstract][Full Text] [Related]
3. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
[TBL] [Abstract][Full Text] [Related]
4. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations.
Zukotynski KA; Valliant J; Bénard F; Rowe SP; Kim CK; Pomper MG; Cho SY
Clin Nucl Med; 2018 Mar; 43(3):213-216. PubMed ID: 29356735
[TBL] [Abstract][Full Text] [Related]
5. Effect of
Wang H; Zhu H; Li G; Dai J; Huang H; Jia Q
Front Med (Lausanne); 2024; 11():1355236. PubMed ID: 38725467
[TBL] [Abstract][Full Text] [Related]
6. PSMA-Targeted PET Radiotracer [
Ismail MS; Peters DE; Rowe SP; Salavati A; Sharma S; Anders RA; Pomper M; Slusher BS; Selaru FM
Clin Exp Gastroenterol; 2023; 16():237-247. PubMed ID: 38090679
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen (PSMA) Uptake in the Scrotum and Epididymis on PET-CT: When is it Pathological?
Singh D; Badya R; Drew Z
Indian J Nucl Med; 2024; 39(1):37-42. PubMed ID: 38817726
[TBL] [Abstract][Full Text] [Related]
8. Unusual Sites of Visceral Spread in Prostate Cancer: A Prostate-Specific Membrane Antigen-Based Theranostic Imaging Series.
Aggarwal P; Sood A; Kumar R; Singh H; Singh H; Bhatia V; Mittal BR
Clin Nucl Med; 2024 May; 49(5):e222-e226. PubMed ID: 38465933
[TBL] [Abstract][Full Text] [Related]
9. Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
Semsarian CR; Ma T; Nickel B; Barratt A; Varma M; Delahunt B; Millar J; Parker L; Glasziou P; Bell KJL
Prostate; 2023 May; 83(6):498-515. PubMed ID: 36811453
[TBL] [Abstract][Full Text] [Related]
10. Translational Molecular Imaging of Prostate Cancer.
Kiess AP; Cho SY; Pomper MG
Curr Radiol Rep; 2013 Sep; 1(3):216-226. PubMed ID: 24159427
[TBL] [Abstract][Full Text] [Related]
11.
Froehner M; Görner M; Merkle L; Kopka K; Zöphel K
Urology; 2024 Feb; ():. PubMed ID: 38423393
[No Abstract] [Full Text] [Related]
12. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Hope TA; Eiber M; Armstrong WR; Juarez R; Murthy V; Lawhn-Heath C; Behr SC; Zhang L; Barbato F; Ceci F; Farolfi A; Schwarzenböck SM; Unterrainer M; Zacho HD; Nguyen HG; Cooperberg MR; Carroll PR; Reiter RE; Holden S; Herrmann K; Zhu S; Fendler WP; Czernin J; Calais J
JAMA Oncol; 2021 Nov; 7(11):1635-1642. PubMed ID: 34529005
[TBL] [Abstract][Full Text] [Related]
13. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific Membrane Antigen PET in Prostate Cancer.
Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA
Radiology; 2021 May; 299(2):248-260. PubMed ID: 33787338
[TBL] [Abstract][Full Text] [Related]
16. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Niaz MJ; Sun M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Front Oncol; 2021; 11():630589. PubMed ID: 33680970
[TBL] [Abstract][Full Text] [Related]
18. Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
Sun J; Lin Y; Wei X; Ouyang J; Huang Y; Ling Z
Front Oncol; 2021; 11():649171. PubMed ID: 33981607
[No Abstract] [Full Text] [Related]
19. How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?
True LD; Chen DL
Clin Cancer Res; 2021 Jul; 27(13):3512-3514. PubMed ID: 33893158
[TBL] [Abstract][Full Text] [Related]
20. Intra-patient comparison of physiologic
Osman MM; Iravani A; Hofman MS; Hicks RJ
Cancer Imaging; 2021 Apr; 21(1):35. PubMed ID: 33863390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
